HER2-POSITIVE BREAST CARCINOMA
Clinical trials for HER2-POSITIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stop aggressive breast cancer in its tracks
Disease control OngoingThis phase 3 study tests whether adding tucatinib to the targeted therapy T-DM1 can better prevent HER2-positive breast cancer from coming back in high-risk patients. About 1,056 participants who still have cancer after initial treatment will receive either T-DM1 alone or T-DM1 p…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New hope for Drug-Resistant breast cancer: experimental combo shows promise
Disease control OngoingThis study tests a new drug (TVB-2640) combined with standard therapies in people with HER2-positive breast cancer that has spread and stopped responding to treatment. The goal is to see if this combination can shrink tumors or slow the disease. The trial involves 17 adults with …
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New drug cocktail shows promise for aggressive breast cancer
Disease control OngoingThis study tests a combination of two drugs, niraparib and trastuzumab, in people with metastatic HER2-positive breast cancer. The goal is to see if the combo is safe and can shrink tumors or slow the disease. About 46 women with advanced cancer that has spread will take part.
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy targets hard-to-treat HER2 cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New PET scan may predict breast cancer treatment success before surgery
Diagnosis OngoingThis study tests whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to targeted therapy (trastuzumab and pertuzumab) before surgery. About 18 women with locally advanced breast cancer will receive the scan and t…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated May 17, 2026 02:02 UTC
-
PET scans may guide breast cancer treatment decisions
Diagnosis OngoingThis study tests whether a special PET/CT scan (FDG-PET/CT) can predict how well HER2-positive breast cancer responds to chemotherapy before surgery. About 235 adults with stage II-III breast cancer will get a scan early in treatment to see if it accurately identifies who will ha…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Diagnosis
Last updated May 11, 2026 20:53 UTC
-
Can vaccines keep breast cancer away? new study tests two options
Prevention OngoingThis study tests two vaccines designed to prevent breast cancer from returning in people who have already been treated for HER2-positive breast cancer. About 119 participants who had chemotherapy and surgery but still had cancer cells left will receive one of the vaccines. The go…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Prevention
Last updated May 11, 2026 20:38 UTC
-
Blood test could spot hidden cancer cells after breast cancer surgery
Knowledge-focused TerminatedThis study looks at whether a blood test that finds tiny bits of tumor DNA can help doctors know if early-stage breast cancer patients still have cancer cells after treatment. About 350 people with stage I-III breast cancer will give blood samples and tumor tissue. The goal is to…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated May 17, 2026 02:07 UTC
-
Scientists peek inside tumors to see how new drug fights HER2 cancers
Knowledge-focused OngoingThis early-phase study looks at how the drug DS-8201a affects tumor cells and the immune system in people with advanced HER2-positive cancers that have stopped responding to standard treatments. Researchers will take small tumor samples before and after treatment to measure chang…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC